{
  "abstract": "The competing interest statement of this article by Robert Howard and Helen Kales (BMJ 2023;382:p1852; doi:10.1136/bmj.p1852) has been amended to note that Robert Howard was an unpaid member of the scientific board of Synaptogenix. The article has now been recategorised as an Opinion.",
  "authors": [
    {
      "affiliations": [],
      "name": "British Medical Journal Publishing Group"
    }
  ],
  "title": "New treatments for Alzheimer’s disease",
  "uid": "0d53c493-cfb4-51f7-a929-7087ed53935c"
}